HEPA Insider Trading

Insider Ownership Percentage: 1.95%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Hepion Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Hepion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20k$0$20kTotal Insider BuyingTotal Insider Selling

Hepion Pharmaceuticals Share Price & Price History

Current Price: $0.14
Price Change: Price Decrease of -0.1858 (-57.74%)
As of 01/22/2025 04:28 PM ET

This chart shows the closing price history over time for HEPA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$0.32Closing price on 01/21/25:

Hepion Pharmaceuticals Insider Trading History

See Full Table
Insider Buying at Hepion Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Hepion Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Hepion Pharmaceuticals (NASDAQ:HEPA)

17.24% of Hepion Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HEPA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$32kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$40k-$20k$0$20k$40kTotal InflowsTotal Outflows
Hepion Pharmaceuticals logo
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Read More on Hepion Pharmaceuticals

Today's Range

Now: $0.14
Low: $0.12
High: $0.14

50 Day Range

MA: $0.57
Low: $0.32
High: $0.69

52 Week Range

Now: $0.14
Low: $0.12
High: $3.49

Volume

32,157,472 shs

Average Volume

2,643,637 shs

Market Capitalization

$946,560.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Who are the company insiders with the largest holdings of Hepion Pharmaceuticals?

Hepion Pharmaceuticals' top insider shareholders include:
  1. Robert T Foster (CEO)
  2. Peter Wijngaard (Director)
Learn More about top insider investors at Hepion Pharmaceuticals.